BYDUREON Monotherapy versus Metformin, Sitagliptin, and Pioglitazone A 26-week, randomized, comparator-controlled trial was conducted to compare the safety and efficacy of BYDUREON to metformin, sitagliptin, and pioglitazone in patients with type 2 diabetes whose glycemic control was inadequate with diet and exercise (Trial 3 - NCT00676338)
Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis
are employees and shareholders of AstraZeneca
It is unusual to have 1:1 comparative trials addressing this issue on similar drugs from different innovators but this barrier has been crossed for these 2 drugs
In patients above age 65, consider adding resistance exercise programming and ensuring dietary protein intake of at least 1.2 g/kg ideal body weight per day
New Evidence on Cancer Progression and Survival Perhaps the most intriguing findings have emerged from recent oncology research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
